Review



iu il 2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems iu il 2
    Iu Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 926 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/Recombinant+Human+IL-2+Protein/pmc13103101-251-48-50
    Average 96 stars, based on 926 article reviews
    iu il 2 - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.
    Article Snippet: Jurkat T cells used in this study were cultured with 5% CO2 at 37 °C, at a concentration of 2 × 10 5 to 5 × 105 inRPMI (Gibco, Thermofisher), with 10% FBS (VivaCell, C04002) and supplementedwith 1% penicillin/streptomycin. .. HumanT or CAR-T cells were cultured in X-VIVO (Lonza, 04-418Q) with 10% FBS (Gibco, 10100-147), 1% GlutaMAX (Gibco, 35050061), 1% NEAA (Gibco, 11140050), 1% Antibiotic-Antimycotic (Gibco, 15240062), 100 IU IL-2 (R&D Systems, 202-IL) and Dynabeads Human T-activator CD3/CD28 (Gibco, 1132D). .. HEK-293T cells were cultured in DMEM with 10% FBS (VivaCell, C04001) and 1% penicillin/streptomycin.

    Article Title: Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function.
    Article Snippet: .. PBMCs from healthy donors were isolated from buffy coats by density gradient using FillPaque (GE) as previously described in refs. 27,30 Primary human T cells were cultured in AIM-V medium (Invitrogen 12055-083) supplemented with 5% human serum (Sigma H4522-100ML), 1% Pen/Strep (Thermo Fisher 15140-122) (T-cell media), and 40 IU IL-2 (R&D Systems #202-IL-10). ..

    Article Title: Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function
    Article Snippet: PBMCs from healthy donors were isolated from buffy coats by density gradient using FicollPaque (GE) as previously described , . .. Primary human T cells were cultured in AIM-V medium (Invitrogen 12055-083) supplemented with 5% Human serum (Sigma H4522-100ML), 1% Pen/Strep (Thermofisher 15140-122) (T cell media), and 40 IU IL-2 (R&D Systems #202-IL-10). ..

    Article Title: Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs
    Article Snippet: Jurkat T cells used in this study were cultured with 5% CO 2 at 37 °C, at a concentration of 2 × 10 5 to 5 × 10 5 in RPMI (Gibco, Thermofisher), with 10% FBS (VivaCell, C04002 ) and supplemented with 1% penicillin/streptomycin. .. Human T or CAR-T cells were cultured in X-VIVO (Lonza, 04-418Q) with 10% FBS (Gibco, 10100-147), 1% GlutaMAX (Gibco, 35050061), 1% NEAA (Gibco, 11140050), 1% Antibiotic-Antimycotic (Gibco, 15240062), 100 IU IL-2 (R&D Systems, 202-IL) and Dynabeads Human T-activator CD3/CD28 (Gibco, 1132D). .. HEK-293T cells were cultured in DMEM with 10% FBS (VivaCell, C04001 ) and 1% penicillin/streptomycin.

    Article Title: Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function
    Article Snippet: .. PBMCs from healthy donors were isolated from buffy coats by density gradient using FillPaque (GE) as previously described in refs. , Primary human T cells were cultured in AIM-V medium (Invitrogen 12055-083) supplemented with 5% human serum (Sigma H4522-100ML), 1% Pen/Strep (Thermo Fisher 15140-122) (T-cell media), and 40 IU IL-2 (R&D Systems #202-IL-10). ..

    Isolation:

    Article Title: Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function.
    Article Snippet: .. PBMCs from healthy donors were isolated from buffy coats by density gradient using FillPaque (GE) as previously described in refs. 27,30 Primary human T cells were cultured in AIM-V medium (Invitrogen 12055-083) supplemented with 5% human serum (Sigma H4522-100ML), 1% Pen/Strep (Thermo Fisher 15140-122) (T-cell media), and 40 IU IL-2 (R&D Systems #202-IL-10). ..

    Article Title: Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function
    Article Snippet: .. PBMCs from healthy donors were isolated from buffy coats by density gradient using FillPaque (GE) as previously described in refs. , Primary human T cells were cultured in AIM-V medium (Invitrogen 12055-083) supplemented with 5% human serum (Sigma H4522-100ML), 1% Pen/Strep (Thermo Fisher 15140-122) (T-cell media), and 40 IU IL-2 (R&D Systems #202-IL-10). ..



    Similar Products

    96
    R&D Systems iu il 2
    Iu Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/Recombinant+Human+IL-2+Protein/pmc13103101-251-48-50
    Average 96 stars, based on 1 article reviews
    iu il 2 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Novartis iu il 2
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Iu Il 2, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/2+il+iu/pmc12982444-74-21-25
    Average 86 stars, based on 1 article reviews
    iu il 2 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Terumo BCT texmacs gmp complete medium with il-2 supplement (200 iu/ml) media bag
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Texmacs Gmp Complete Medium With Il 2 Supplement (200 Iu/Ml) Media Bag, supplied by Terumo BCT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/texmacs+gmp+complete+medium+with+il+2+supplement++200+iu+ml++media+bag/us12359170-1311-26-43
    Average 90 stars, based on 1 article reviews
    texmacs gmp complete medium with il-2 supplement (200 iu/ml) media bag - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    R&D Systems iu recombinant human il 2
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Iu Recombinant Human Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/Recombinant+Human+IL-2+Protein/pmc12170346-262-20-24
    Average 96 stars, based on 1 article reviews
    iu recombinant human il 2 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    Novartis il-2 (20 iu/ml; novartis)
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Il 2 (20 Iu/Ml; Novartis), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/il2/pmc12082382-163-37-40
    Average 90 stars, based on 1 article reviews
    il-2 (20 iu/ml; novartis) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Novartis il-2 500 iu/ml proleukin
    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous <t>IL-2.</t> (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.
    Il 2 500 Iu/Ml Proleukin, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/iu+il+2/il+2+proleukin/pmc12075070-22-31-30
    Average 90 stars, based on 1 article reviews
    il-2 500 iu/ml proleukin - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous IL-2. (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.

    Journal: Frontiers in Immunology

    Article Title: Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

    doi: 10.3389/fimmu.2026.1761397

    Figure Lengend Snippet: CliniMACS Prodigy-manufactured BDCA2 CAR NK cells strongly inhibit tumor growth in vivo when supplemented with exogenous IL-2. (A) On day -7, NSG mice received 5x10 5 RS4;11/BDCA2 cells intravenously. On day 0, mice were intravenously injected with 1x10 7 CAR NK cells or an equivalent number of UTD NK cells. Subcutaneous injections of IL-2 (25,000 U/day) were given to indicated mouse groups from day -1 to day 8. Tumor growth was monitored every two to three days using bioluminescence imaging (BLI). Total flux (B) and representative BLI images (C) were recorded. Data are represented as mean ± SD. Statistical significance was analyzed by two-way ANOVA. **** p < 0.0001; ns: p > 0.05.

    Article Snippet: Two groups of animals, treated with either UTD NK cells or BDCA2 CAR NK cells, received daily subcutaneous injections of 25,000 IU IL-2 (Proleukin S; Novartis Pharma, Nürnberg, Germany), starting one day before (day -1) and continuing through nine days after NK cell treatment (day 8).

    Techniques: In Vivo, Injection, Imaging

    Flow cytometric analysis of the in vivo persistence of tumor cells and NK cells. At the conclusion of the experiment, the persistence of tumor cells (A) , NK cells (B) , and CAR NK cells (C) in the bone marrow, blood and spleen was determined by flow cytometry for mice treated with CAR NK cells with or without exogenous IL-2 support. Data are represented as mean ± SD. Statistical significance was analyzed by two-tailed, unpaired Student’s t-test. **** p < 0.0001; * p < 0.05; ns: p > 0.05.

    Journal: Frontiers in Immunology

    Article Title: Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

    doi: 10.3389/fimmu.2026.1761397

    Figure Lengend Snippet: Flow cytometric analysis of the in vivo persistence of tumor cells and NK cells. At the conclusion of the experiment, the persistence of tumor cells (A) , NK cells (B) , and CAR NK cells (C) in the bone marrow, blood and spleen was determined by flow cytometry for mice treated with CAR NK cells with or without exogenous IL-2 support. Data are represented as mean ± SD. Statistical significance was analyzed by two-tailed, unpaired Student’s t-test. **** p < 0.0001; * p < 0.05; ns: p > 0.05.

    Article Snippet: Two groups of animals, treated with either UTD NK cells or BDCA2 CAR NK cells, received daily subcutaneous injections of 25,000 IU IL-2 (Proleukin S; Novartis Pharma, Nürnberg, Germany), starting one day before (day -1) and continuing through nine days after NK cell treatment (day 8).

    Techniques: In Vivo, Flow Cytometry, Two Tailed Test